BioTuesdays

Alterity underscores published data on role of iron in neurodegenerative diseases

Alterity Therapeutics

Alterity Therapeutics (ASX:ATH, NASDAQ:ATHE) has highlighted a peer-reviewed article published in Metallomics, emphasizing the significance of iron and iron-targeting agents, such as the company’s ATH434, in treating neurodegenerative diseases.

The publication, titled ATH434: a promising iron-targeting compound for treating iron regulation disorders, was authored Ashley Pall from the Department of Pharmaceutical Sciences at Wayne State University.

David Stamler, M.D., CEO of Alterity, stated, “Iron has long been implicated in neurodegeneration, but having the appropriate iron-targeting agent is critical to having a positive impact on treating disease. This ground-breaking publication demonstrates the novel way in which ATH434 targets the labile, or reactive, form of iron which can be so damaging to cells when in excess. ATH434 acts as an iron chaperone to redistribute this excess reactive iron, thereby reducing protein aggregation and oxidative stress in the brain and rescuing neuronal function.”